Lithium in depression: a review of the antidepressant and prophylactic effects of lithium.
The therapeutic effects of lithium in depression are reviewed. The acute antidepressant effect of lithium alone is neither as impressive nor as predictable as its antimanic action, nor is it equivalent to that of tricyclic antidepressants. In patients who are 'refractory' to tricyclics or monoamine oxidase inhibitors, combined treatment with lithium may augment antidepressant response. Lithium is an effective prophylactic treatment in both unipolar and bipolar disorder and in the latter is the drug of choice. Aspects of monitoring, such as range of therapeutic plasma levels, dosage regimen and adverse effects, are discussed. Current evidence suggests that, in patients who fail to respond to lithium or are unable to tolerate side-effects, carbamazepine should be considered.
Johnson
G F
GF
Department of Psychiatry, University of Sydney, NSW.
D000928:Antidepressive Agents / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D008094:Lithium / Q000097:blood / Q000627:therapeutic use*; D012008:Recurrence
D000928:Antidepressive Agents; D002220:Carbamazepine; D008094:Lithium